1)
A key omission appears to be the costs analysis. This is obviously a very important outcome (listed in the protocol), which needs reporting.
2) In the discussion the authors mention PREMs and PROMs butaside from wellbeing -I think a limitation of this study is that not enough of these outcomes were assessed (with maybe too much focus on clinical outcomes). It"s perhaps not too surprising that the setting had no effect on the clinical outcomes studied. Although it is without doubt useful to have this confirmed in this trial, there may nevertheless have been more subtle effects of the setting facilities which may have been picked up using additional outcomes, such as, say, patient satisfaction. Furthermore, patients could have been asked/surveyed about other issues which might be important to this patient population -perhaps things like physical comfort or emotional support? (which could have differed across the settings). I particularly think these points are worth mentioning for the sake of any future trials. The abstract concludes: "This treatment setting may confer social benefits to patients and economic benefits to healthcare providers" -there is minimal data on the former and none on the latter.
3) It is evident from reading the trial registry entry and the protocol that the trial began as a standard parallel group RCT and was then modified to incorporate a preference component. However, his is not totally clear (to me) from reading the methods section -briefly tell the story of what happened and how and why you adapted the methods.
(4) In the methods I would state whether ambulatory care for women with NVP was available before the trial began, or whether the facilities arose because of the trial (it seems the latter?). This could provide further justification for broadening the study design -i.e. with only a randomized cohort it is possible that the trial may have recruited a population with an inflated proportion of patients who wanted treating as outpatients (since participating in the trial was the only way of receiving outpatient treatment) and a reduced proportion of patients wanting inpatient treatment (since not participating would be the only way to ensure they"re treated as inpatients). The results from such a trial could therefore have been biased.
(5) On a related issue I think p5 line 48 may need rewording. The end of the sentence currently reads "or home-averse patients" but might make more sense as "...and underrepresented by home averse (hospital inclined) patients." (6) P7 line 12 the url takes me to a login page which isn"t useful for informing me on the methods used to randomize. Perhaps a more descriptive text could be used instead, along the lines of "Randomization was carried out centrally via an interactive web response system" -if that is what was used? Was this system suitably robust? Readers need to know whether or not it was possible to manipulate the randomised sequence e.g. could one patient"s allocation have been given to another patient? On the CONSORT list you have "N/A" next to allocation concealment which I don"t think is an acceptable answer (for the randomized cohort of patients).
Other comments:
The trial registration URL on p5 has a typo which means the user is taken to an error page (the comma needs deleting to fix this).
P6 line 12 -would add external before validity P10 lines 27-32. This list seems short compared to the trial registry list of secondary outcomes. P12 Paragraph on patient characteristics (also Table 1 ) -what"s important to consider for the randomized cohort is clinical significance, rather than statistical significance. See Item 15 description in the CONSORT statement (no need for p-values for the randomized cohort).
The subject is clinical interesting. The study is well conducted and the reasoning for including a patient preferential arm well described. The statistics explained well but in spite of describing needing 60 patients in each group many comparisons are described between sub-groups. The study is underpowered to detect changes within these groups. This also includes changes between the randomized treatment arms and between the patient-preferential arms.
The patients still differ as the patient preferential inpatient arm had higher PUQE-score than those opting for outpatient treatment. Pre-pregnant weight and weight-loss before admission is not stated, why not? In spite of admission BMI being not statistical different between these groups, the weight loss might be different, thus these groups have not been completely described. Is this information available?
I have some further comments I would like the authors to address: Inclusion; how was the consent given by the participating women? Oral or written? This is not stated.
The treatment regimens was not quite similar: different volume of fluid and as I understand for the ambulatory group only an i.v antiemetics bolus was given. Please comment on these differences and their possible influence for the study outcome.
Where other non-medical differences in care between groups? What care was given at the outpatient clinic; attendance by at nurse or midwife during the hours of rehydration? In the conclusion page 18 line 33 it is stated they "would recommend an ambulatory service to manage women with severe NVP as first line with the appropriate medical and nursing/midwifery services to support women". But this actual support has not been described. Clinical data assessed at recruitment:
Gestational age assessed by which method? (L.m.p or sonography?) Dating similar for all patient groups and in both centres?
Were any analyses compared regarding the two different centres? Were the care given (other than fluid -medications) similar in the two centres? Page 9 line 10: "a bolus dose of antiemetic(s) were given during treatment, was this each day they attended the ambulatory or only first day? Page 10 line 41: "was able to tolerate food and drink" By which means was this assessed? "no vomiting for at least 12 hours", assessed at same time span to ensure the effect of sleeping similar in different groups?
I would like to have a more precise sum of the actual medication given in different groups: Antiemetics: i.v or tablets? One or more different medication needed? Ranitidine use in different groups should be described. Missing follow-up at 7 days was quite substantial and not evenly distributed. This could be commented in the discussion.
From which categories were the TOP patients? TOP (termination of pregnancy) was only noted in the ambulatory group. Is this statistically different between groups? As commented TOP is one possible outcome seen when HGtreatment is insufficient/unbearable for the patient. This might be worth elaborating. Table 2 : missing decimal sign in the last column for reduction in drinking score 7 days post discharge.
Page 15 line 47: adding "with" in the sentence " Ambulatory treatment was associated a higher…"
As a patient-preferential arm is included in this study I was rather surprized that no Patient perceived quality or satisfaction of care was included. "Would you recommend this type of treatment to a friend or opt to receive this type of treatment again " is often asked when comparing treatments. Did the authors ever reflect on adding this aspect to the study? They argue in Page 17 line 34 that "patient choice has intrinsic value" as well as in the final conclusion so why have they not really evaluated the experience of choice as an outcome?
The conclusion of the abstract is different from the conclusion in the paper. The line "economic benefits to healthcare providers" is not in the full conclusion and thus should be removed. If this is to be included in any conclusion it has to be really discussed in the discussion first. This particular study however, has not displayed any economic data. 
REVIEWER

GENERAL COMMENTS
The authors present the results of a prospective randomized controlled trial in which pregnant women with symptoms of nausea were randomized to treatment either in hospital or in ambulatory care. Additional non-randomized subjects were also analyzed consisting of patients who indicated a desire for location of treatment.
The abstract does not summarize all the relative results, specifically anti-emetic use at 7 days, eating and drinking scores at 7 days which are different between groups. As written data reporting is selective.
The treatment regimens were not identical -greater fluid quantities were used in the inpatient group. (Intravenous fluids have antiemetic effects which are dose related.) It appears that any of three anti-emetic could be used by clinician preference and no particular rationale or order is given for their use. Drug administration/use is not reported. Consequently the readership could not determine if one group was treated with an agent with low efficacy and the other with high efficacy. The choice of metoclopramide as a first line treatment in in contrast to the RCOG green top guideline in which it is a second line treatment.Adverse events are not reported. Based on the methods as presented, this study could not be replicated without nor could a clinician write a treatment protocol with the information as presented.
The basis of the sample size is not provided.The statistical tests are appropriate to the data. The risk of bias is relatively high as there is no possibility of blinding and the proportion of drop-outs and cross over between groups is high. The authors describe the analysis as intention to treat but some patients dropped out following randomization, entered the non-randomized cohorts and were analyzed in their treatment groups (per protocol analysis). Clinicians would probably find a supplementary per-protocol analysis helpful.
The PUQE score is highest in the non-randomized in patient cohort indicating that baseline nausea levels were higher in this group which may reflect a selection bias -i.e. patients with more severe symptoms opting for inpatient treatmentThe higher baseline PUQUE score may influence response to anti-emetics as efficacy varies with baseline risk.
No statistical analysis is provided relating to effect of treatment within groups. This would be valuable as establishing that inpatient vs. ambulatory treatment are equivalent is of little value if neither is effective.
There appear to be differences between group 1 and 3 to groups 2 and 4 in response to treatment but the authors do no apply the same statistical approach to the outcome data as they do to the baseline data i.e. no direct statistical comparison is provided.
The authors do not state how missing data were handled.
REVIEWER
Avinesh Pillai University of Auckland New Zealand
REVIEW RETURNED
03-Aug-2017
GENERAL COMMENTS
This manuscript is well written and clear. The outcomes (both in the manuscript and the attached protocol), the methodology used, and the results are clearly explained. Regarding the sample size calculation, more women were recruited to the trial than indicated by the sample size calculation, which is great for the analysis and study power. The authors have stated the limitations of the trail, especially the fact that the study was not fully randomised and that the randomised part of the trial could not be blinded, and the bias arising from this. Comment 1) A key omission appears to be the costs analysis. This is obviously a very important outcome (listed in the protocol), which needs reporting.
VERSION 1 -AUTHOR RESPONSE
Response: See above response to the Editor. We have added an explanatory paragraph in result section. With this paper we focused on clinical outcomes. The cost analysis will be analyzed to assess the cost to both the healthcare units and patients themselves in terms of loss of earning, maternity leave pay and the need for additional childcare costs.
Comment 2) In the discussion the authors mention PREMs and PROMs but -aside from wellbeing -I think a limitation of this study is that not enough of these outcomes were assessed (with maybe too much focus on clinical outcomes). It"s perhaps not too surprising that the setting had no effect on the clinical outcomes studied. Although it is without doubt useful to have this confirmed in this trial, there may nevertheless have been more subtle effects of the setting facilities which may have been picked up using additional outcomes, such as, say, patient satisfaction. Furthermore, patients could have been asked/surveyed about other issues which might be important to this patient population -perhaps things like physical comfort or emotional support? (which could have differed across the settings). I particularly think these points are worth mentioning for the sake of any future trials. The abstract concludes: "This treatment setting may confer social benefits to patients and economic benefits to healthcare providers" -there is minimal data on the former and none on the latter.
Response: We agree that PREMS and PROMS are extremely important aspects of management of women with severe NVP/HG. In this paper we focused on clinical outcomes but alongside this trial we ran another study address patient satisfaction of care, the emotional impact of HG and the socioeconomic impact of the condition ("The psychological impact of hyperemesis gravidarum; A two point case control evaluation of psychological symptoms, infant bonding and patient perception of their treatment"). This is currently being analyzed and depending on the results may give evidence to improve the physical and emotional support we offer to women. We have been working with the UK charity Pregnancy Sickness Support with regard educating other healthcare professionals about the impact the condition has on women and we hope that this future publication will raise awareness of the implications HG has for women and their families.
Comment 3) It is evident from reading the trial registry entry and the protocol that the trial began as a standard parallel group RCT and was then modified to incorporate a preference component. However, his is not totally clear (to me) from reading the methods section -briefly tell the story of what happened and how and why you adapted the methods.
Response: This has been added as suggested (lines 171-184). As patient preference of type of care/location of care becomes increasingly important in modern healthcare we agree it"s good to explain why the methodology was altered to reflect the reality of running a non-blinded trial, particularly in a patient population where social situations are important. Although willing to participate in research, randomization was not an appealing option for all given their individual preferences and social situations. We therefore felt that rather than undertaking a small RCT with bias created by the large number of patients declining entry to the trial, it would be preferable to undertaken a combined RCT and patient preference trial Comment 4) In the methods I would state whether ambulatory care for women with NVP was available before the trial began, or whether the facilities arose because of the trial (it seems the latter?). This could provide further justification for broadening the study design -i.e. with only a randomized cohort it is possible that the trial may have recruited a population with an inflated proportion of patients who wanted treating as outpatients (since participating in the trial was the only way of receiving outpatient treatment) and a reduced proportion of patients wanting inpatient treatment (since not participating would be the only way to ensure they"re treated as inpatients). The results from such a trial could therefore have been biased.
Response: Neither of the units offered this service in a systematic fashion, however it was available. During the trial the "default" for women who declined trial entry was in fact outpatient management, though this was not always achieved as the pressures of staff and hospital beds influenced actual management. We found that women who declined trial entry did so entirely because they had a strong preference for inpatient or for outpatient, thus the reviewer"s suggestion that women may have joined the trial to obtain a specific treatment was not the case in this study.
As the trial involved a clinical fellow dedicated to optimizing care in both arms, the service has improved considerably and following the study outcomes, OP management continues in both units as the first line approach to treatment of severe NVP/HG.
In a non-blinded RCT, predetermined patient preference for one treatment arm held by some patients must be considered as a source of bias and although our methodology included combination of randomized and non-randomized patients it may have reduced patient treatment bias in this sense.
Comment 5) On a related issue I think p5 line 48 may need rewording. The end of the sentence currently reads "or home-averse patients" but might make more sense as "...and underrepresented by home averse (hospital inclined) patients."
Response: Yes, we agree this wording is better and has been changed as recommended Comment 6) P7 line 12 the url takes me to a login page which isn"t useful for informing me on the methods used to randomize. Perhaps a more descriptive text could be used instead, along the lines of "Randomization was carried out centrally via an interactive web response system" -if that is what was used? Was this system suitably robust? Readers need to know whether or not it was possible to manipulate the randomised sequence e.g. could one patient"s allocation have been given to another answer (for the randomized cohort of patients).
Response: Thank you for highlighting the point regarding the randomization database. This has now been amended (lines 164-168) including a sentence on allocation concealment (N/A changed to page 7; this was mistakenly written as N/A as it was thought to have been a question regarding how participants/staff were blinded to the intervention.
Comment: The trial registration URL on p5 has a typo which means the user is taken to an error page (the comma needs deleting to fix this).
Response: Thank you, comma removed.
P6 line 12 -would add external before validity
Response: This has been added.
P10 lines 27-32. This list seems short compared to the trial registry list of secondary outcomes.
Response: All the secondary outcomes are now listed in the results section as recommended by the editor. We are conscious of keeping the word count relatively limited and given all secondary outcomes are listed in the tables and now in the document itself it may perhaps be adding wording which is later discussed. In addition, readers will have access to the protocol describing primary and secondary outcomes.
P12 Paragraph on patient characteristics (also Table 1 ) -what"s important to consider for the randomized cohort is clinical significance, rather than statistical significance. See Item 15 description in the CONSORT statement (no need for p-values for the randomized cohort).
Response: For the non-randomized cohort, we used the p values to demonstrate there was no statistical difference in presenting symptoms/patient characteristics, demonstrating they reflected the same population rather than a different group which would make combining the randomized and nonrandomized data justified. After undertaking review of several papers in other peer reviewed articles p values are used for randomized groups to confirm that the process of randomization was adequate.
Reviewer: 2
Reviewer Name: Jone Trovik Institution and Country: Dpt. of obstetrics and gynaecology, Haukeland University hospital, Bergen, Norway; Department of Clinical Science, University of Bergen, Bergen, Norway Please state any competing interests or state "None declared": None declared
Please leave your comments for the authors below Comment: The authors have conducted a randomized controlled study of short-term outcomes of ambulatory care versus inpatient treatment for Hyperemesis gravidarum. Due to accrual rates a patient preferential arm was added. Power calculations performed was estimated to need two groups of 60 patients each to detect a difference of 0.6 SD in PUQE score.
Response: Following the start of the trial it became apparent that an RCT only design was not feasible due to strong patient preference and hence the change in methodology. The power calculation used for the RCT was maintained given the primary outcome was the same.
The change in methodology was undertaken to enable a number of participants powered to detect any significant difference. We included the outcomes of the individual RCT and PPT in the tables as we felt this may be of interest to readers. In the discussion section it is acknowledged that the individual components are underpowered to detect any significant difference in PUQE score at 48 hours and hence the need for a combined analysis.
Comment: The patients still differ as the patient preferential inpatient arm had higher PUQE-score than those opting for outpatient treatment.
Response: Yes, this difference is shown within the tables but was not statistically significant.
Comment: Pre-pregnant weight and weight-loss before admission is not stated, why not? In spite of admission BMI being not statistical different between these groups, the weight loss might be different, thus these groups have not been completely described. Is this information available?
Response: Weight change at 7 days following discharge was the only secondary outcome used and is now included in the main text. Pre-pregnancy weight was not available for women and weight loss prior to presentation was not recorded. We found many patients did not know their pre-pregnancy weight nor the amount of weight they lost prior to presenting to hospital and any information would therefore not have been accurate. Weight change was not significant in either group between presentation and 7 days following discharge and from discharge to 7 day discharge review.
I have some further comments I would like the authors to address:
Comment: Inclusion; how was the consent given by the participating women? Oral or written? This is not stated.
Response: Written consent was taken. This has now been added (lines 157)
Comment: The treatment regimens was not quite similar: different volume of fluid and as I understand for the ambulatory group only an i.v antiemetics bolus was given. Please comment on these differences and their possible influence for the study outcome.
Response: The aim of the trial was to assess if the two different treatment protocols were equally effective at improving HG. The trial treatment regimens were as similar as we could make them, while taking account of the different treatment settings. We could not provide systemic treatment at home, and we would not have felt it ethical to withhold the higher volume of fluids or regular systemic antiemetics in women who were inpatients anyway. We also wanted to compare the "new" ouptaient treatment with the "old" conventional inpatient management regime as this was what was being used currently in most hospitals.
The primary outcome was to establish if rapid outpatient treatment was as effective as slower inpatient rehydration. The participants in the OP group received 2 litres of fluid over a period of 4 hours; this was the minimum amount of time for treatment as patients received fluid containing 20mmol potassium chloride per litre which has a minimum running time of 2 hours. Inpatients received fluid more slowly over their admission and overall a higher volume (see protocol). The concept of ambulatory care was that women spend as little time in hospital as possible. Women treated as inpatients were given regular anti-emetics which were available via IV/IM/PO routes. The protocol for ambulatory care included bolus dose IV medication as this was not available to them at home and it was considered this may be beneficial to maintain symptom control prior to their next treatment session.
Women in the outpatient group were asked to take regular oral anti-emetics between treatment sessions. This included a buccal medication in case they were not able to tolerate oral tablets.
Comment: Where other non-medical differences in care between groups? What care was given at the outpatient clinic; attendance by at nurse or midwife during the hours of rehydration? In the conclusion page 18 line 33 it is stated they "would recommend an ambulatory service to manage women with severe NVP as first line with the appropriate medical and nursing/midwifery services to support women". But this actual support has not been described.
Response: The differences in the care given to patients in terms of medications were that 2 boluses of IV anti-emetic for the OP group were given in 24 hours compared to regular dosages in the IP route. The women in the IP ward were cared for by surgical nursing staff with gynaecology experience and the ambulatory care women were cared for in a specialist ambulatory unit where the nursing staff were given training on caring for gynaecology patients prior to the start of the trial. Fluid for inpatients was given as per protocol with a total of 4 liters over a 24-hour period.
We did not "measure" the non-pharmaceutical support given to women in each group and we agree that this may have influenced outcomes either way. Women may also have benefited differently in family support during the study depending on whether they were isolated form their families during the treatment schedule. This is more qualitative data where ours study was quantitative in design.
Our conclusion to recommend ambulatory care was based on efficacy in light of NHS bed pressures and costs and a trial by McParlin et al which describes the benefit of having a telephone support system3. We agree that adding the unsubstantiated comment on support is not evidence based from our study data and we have changed our concluding recommendation.
During our trial patients had access to the researchers via email and we offered a lot of support to our participants. We have also worked with the charity Pregnancy Sickness Support (PSS) who advocate more support for women suffering with HG. Our group previously conducted a meta-analysis which found a strong association between HG and depression and anxiety4. A suggestion on the type of support has been added (line).
Comment: Did the patients have similar access to supplementary food and drink inpatient as outpatients?
Response: No specific supplements were given to either group but as part of routine antenatal care a dietician referral was made if BMI was 18 or less. If clinicians were concerned regarding weight loss a dietician referral was made at clinician"s discretion. This was available to women in both groups and 7 women (4 inpatients, 3 outpatients) received dietary supplements ("Ensure" drinks). A sentence regarding this has been added to explain this process (lines 516-519) Comment: The inclusions of patients were that always done at the same time of day? The authors have used PUQE-12, amounting to the last 12 hours. This might be different whether including 8 hours of sleep within this score (hours sleeping might not lead to counting of nausea in the same amount as the wake hours? Where PUQE-scoring performed at approximately same time of day for the different groups?
Response: The study was designed using the validated PUQE-12 scoring system. The following sentence has been added as a limitation "At the time the trial was designed the PUQE-12 version was the only validated method of symptom assessment and hence was used in the protocol. This tool is a reflection of symptoms over the last 12 hours).
A 24 hour version has now been developed and validated (PUQE-24) as some of the previous time in a 12 hour window may be spent sleeping and hence this is likely to be a more accurate reflection of symptoms5. We would recommend this for use in clinical practice and in future research" For trial purposes the PUQE score was carried out at roughly the same time for inpatients and prior to treatment for outpatients who attended every day either for a morning or afternoon session. Response: An addition has been made regarding this (lines 231-33). The eating and drinking scores were arbitrary as no specific o validated measures of oral intake were available. Patients were not asked to complete food diaries as they completed the symptom questionnaire which was combined with other clinical information. Although food diaries would be a useful qualitative measure it may have been difficult to analyze the data for them in this trial. Fluid balance was not used in addition to oral intake.
Comments: Clinical data assessed at recruitment.
Comment: Gestational age assessed by which method? (L.m.p or sonography?) Dating similar for all patient groups and in both centres?
Response: In both centers gestation was based on ultrasound scan as all women recruited to the trial (and indeed all those treated for HG) were offered an US scan. On admission if a scan had not yet been performed estimated gestation was based on LMP (if known).
Comment: Were any analyses compared regarding the two different centres? Were the care given (other than fluid -medications) similar in the two centres?
Response: Both units operated using the same guideline and study protocol. The only difference was that at St Mary"s Hospital women having ambulatory care were treated in the gynecology ward rather than the ambulatory care unit due to increased capacity of ambulatory care facilities. Since the completion of the trial Chelsea and Westminster Hospital have opened a new gynecology unit which now accommodates the ambulatory care patients being treated for HG.
Page 9 line 10: "a bolus dose of antiemetic(s) were given during treatment, was this each day they attended the ambulatory or only first day?
Response: Women in the OP group received bolus dose(s) of IV medication at each attendance (lines). If they were taking more than one antiemetic a bolus dose of one anti-emetic (usually IV) was given at the start of treatment, then a second agent at the end of treatment prior to discharge home. These women were advised when their next dose of oral medication would be due.
Page 10 line 41: "was able to tolerate food and drink" By which means was this assessed? "no vomiting for at least 12 hours", assessed at same time span to ensure the effect of sleeping similar in different groups?
Response: As discussed above, using the 12 hour PUQE scale is a limitation and the 24 hour version would now be advised. The PUQE score was used as measure of severity rather than an indicator of fitness for discharge.
The discharge criteria used for the study were; able to tolerate food and drink (without vomiting), no vomiting for at least 12 hours and absence of ketonuria. It has subsequently been reported that ketosis is not a reliable indicator of severity of NVP symptoms6 as ketosis is a reflection of starvation and lipolysis7 rather than dehydration and hence indicates poor oral intake; we therefore saw a reduction in ketonuria with improved oral intake.
Comment: I would like to have a more precise sum of the actual medication given in different groups: Antiemetics: i.v or tablets? One or more different medication needed? Ranitidine use in different groups should be described.
Response: The treatment protocols are provided as supplementary material. The paper would be excessively long if included but the protocol is freely available.
The anti-emetics used operated on a 1st/2nd/3rd line system. Daily clinical review was used to determine if the treatment needed to be increased. All anti-emetics were prescribed and given regularly during admission or at the start and completion of daily treatment in the outpatient group. Routes of administration was based on oral tolerance and patient preference. Ranitidine was given to patients in both groups where women reported epigastric pain or reflux. As this was not a trial of individual antemetic efficacy, the number or route of administration of anti-emetics was not recorded or used as a secondary outcome in this trial.
In our forthcoming trial we have assessed whether women described classed as having "severe" form HG (use of 3rd line anti-emetics/>5 days admission/3 or more admissions or outpatient attendances) have a worse experience of hospital care, suffer greater psychological symptoms and bond less well with their babies.
Comment: Did no patients receive any i.v or enteral nutritional supplementation?
Response: None of our patients required enteral feeding or total parenteral nutrition. In the UK this is used as a "last resort" for women continuing to lose weight despite maximum therapy. A recent trial published by Grooten et al did not demonstrate any benefit from early enteral (NG) feeding and reported that it was poorly tolerated by patients9
Comment: Sick-leave/absence from caregiving have this been noted?
Response: This data has been collected in our parallel study so as to include information from the whole pregnancy. We look forward to publishing this in due course.
Results: Comment: Inclusion dates (month-year start and stop)
Response: This information is at the beginning of the methods section.
Comment: Missing follow-up at 7 days was quite substantial and not evenly distributed. This could be commented in the discussion. From which categories were the TOP patients?
Response: The number of women completing the follow-up was 125 (83%) which we felt was reasonable, especially as many women were likely to have ongoing symptoms which may have reduced their ability to participate in the follow-up. The 7 days post discharge follow-up was offered as a face to face consultation or telephone discussion. The 6 women who underwent TOP prior to the follow-up were all in the PPT.
We did not ask women specifically about their reasons for TOP and have not attempted to extrapolate conslusion from this group. One women from the group also withdrew making the follow-up rate of eligible patients in this group 89%. Section added to discussion (lines 446-457)
Comment: TOP (termination of pregnancy) was only noted in the ambulatory group. Is this statistically different between groups?
As commented TOP is one possible outcome seen when HG-treatment is insufficient/unbearable for the patient. This might be worth elaborating. TOP was only reported in the PPT group as added to the discussion section. Numbers in this study are insufficient to determine if this was significant and the study was not designed to include this as an outcome. Nevertheless, it is a notable finding.
Response: The Pregnancy Sickness Support Charity estimates that as many as 10% of women with HG undergo TOP due to their symptoms10 and that many more are likely to have considered this option. This will be discussed further in our forthcoming paper on the psychological impact of severe NVP/HG as described above. Table 2 : missing decimal sign in the last column for reduction in drinking score 7 days post discharge.
Response: Thank you, corrected.
Response: Thank you, corrected Comment: As a patient-preferential arm is included in this study I was rather surprized that no Patient perceived quality or satisfaction of care was included. "Would you recommend this type of treatment to a friend or opt to receive this type of treatment again " is often asked when comparing treatments. Did the authors ever reflect on adding this aspect to the study? They argue in Page 17 line 34 that "patient choice has intrinsic value" as well as in the final conclusion so why have they not really evaluated the experience of choice as an outcome?
Response: Thank you, we agree that patient feedback and experience of care is of upmost importance. As previously discussed a parallel study was conducted ("The psychological impact of hyperemesis gravidarum; A two point case control evaluation of psychological symptoms, infant bonding and patient perception of their treatment"). This included two evaluations of patient experience; the Picker Patient Experience Questionnaire and the Patient Evaluation of Emotional Care during hospitalization (PEECH). I have attached the protocol for reviewers to read should they wish. One must also consider that satisfaction will be influenced by women receiving the treatment they preferred and adds weight to having a combined RCT/PPT methodology approach as women in an RCT only design study not assigned to their preferred treatment are likely to be more dissatisfied which adds a source of bias to the overall results.
Response: The trial protocols are supplied as supplementary information. The anti-emetics used in the trial were given in a step-wise approach as per protocol (see trial protocol). The first line agents were cyclizine, metoclopramide and Buccastem (sub-lingual stemetil). (The RCOG guidance was published shortly after the trial had finished and hence metoclopramide was used as a first line agent during this study). The second line agent was ondansetron and the third line agent was systemic steroid treatment (hydrocortisone) followed by prednisolone if initial treatment effective and when oral medication was tolerated. The protocols were clearly in place regarding the stepwise use of antiemetics. Decision to increase anti-emetic agents was based on patient response. The trial was not an assessment of drug efficacy and all women in both arms received the same stepwise approach to anti-emetic therapy. I do agree further high quality research into drug efficacy is needed for management of HG as concluded by the recent Cochrane review2. One adverse incident occurred during the trial and this has been added (lines 374-377)
Comment: The basis of the sample size is not provided. The statistical tests are appropriate to the data. The risk of bias is relatively high as there is no possibility of blinding and the proportion of dropouts and cross over between groups is high. The authors describe the analysis as intention to treat but some patients dropped out following randomization, entered the non-randomized cohorts and were analyzed in their treatment groups (per protocol analysis). Clinicians would probably find a supplementary per-protocol analysis helpful.
Response: The power calculation for the RCT was based on detecting a difference of 0.6 standard deviations of the mean. This power calculation was carried over to the combined RCT and PPT study given no significant differences in patient characteristics or presenting symptoms were identified. In an RCT only study the risk of bias and drop outs is high given the intervention could not be blinded.
As discussed above this adds weight to the addition of the PPT for women wishing to participate but with specific treatment location preferences. The trial was intention to treat with the exception of patients who withdrew from the RCT prior to starting their preferred treatment protocol. These patients were analysed as non-randomized participants as their decision not to participate in the RCT was made prior to any treatment being given.
Comment: The PUQE score is highest in the non-randomized in patient cohort indicating that baseline nausea levels were higher in this group which may reflect a selection bias -i.e. patients with more severe symptoms opting for inpatient treatment. The higher baseline PUQUE score may influence response to anti-emetics as efficacy varies with baseline risk.
Response: Thank you. This has been mentioned in the results section and a further point has been made in the results and discussion sections (lines 348 and 451-57).
Comment: No statistical analysis is provided relating to effect of treatment within groups. This would be valuable as establishing that inpatient vs. ambulatory treatment are equivalent is of little value if neither is effective.
Response: The aim of our study was to compare an existing treatment (inpatient) with an alternative treatment (outpatient). We know that actual effectiveness of any treatment for hyperemesis is controversial and in fact we are supporting until spontaneous improvement rather than "treating". However this is outwith our study design. Under the heading "treatment efficacy" on page 15 the reduction in PUQE score for the IP and OP groups is stated and shown in tables 2 and 3. A sentence has been added in this section to reflect that other symptom scales also improved in both groups.
Comment: There appear to be differences between group 1 and 3 to groups 2 and 4 in response to treatment but the authors do no apply the same statistical approach to the outcome data as they do to the baseline data i.e. no direct statistical comparison is provided.
